Canada should give biopharmaceutical firms patent term extensions to recover time lost due to mandatory regulatory and marketing approvals.
Canadian policy-makers should enact legislation to define rare diseases and encourage Canadian firms to intensify their research and development of new therapies, writes Kristina Lybecker. Victor Casale photograph courtesy of Flickr
VANCOUVER, B.C. / Troy Media/ – As the old adage states, “You’ll be known by the company you keep.” As such, the implications for Canada’s biopharmaceutical sector are rather dismal.
People. Policy. Politics. This is an exclusive subscriber-only story.
Conservative MPs and strategists agree that appointing former Harper cabinet minister John Baird to lead the election post-mortem is the right call. 'He does not hold any punches,' says Conservative MP Stephanie Kusie.